Journal of Diagnostics Concepts & Practice >

2026 , Vol. 25 >Issue 03: 249 - 259

DOI: https://doi.org/10.16150/j.1671-2870.2026.03.001

Expert forum

Current status and research advances in laboratory diagnosis of non-tuberculous mycobacteria

  • HUANG Hui ,
  • ZHANG Tingting ,
  • SUN Hongli
Expand
  • a Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijin 100730, China
    b Department of Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijin 100730, China

Received date: 2025-12-30

  Revised date: 2026-01-23

  Accepted date: 2026-03-04

  Online published: 2026-06-27

Fold

Abstract

Non-tuberculous mycobacteria (NTM) are a group of opportunistic pathogens widely present in the environment. The global incidence of NTM infections and associated drug resistance rates are increasing. Although unified global surveillance data are lacking, studies based on national surveillance or large-scale databases from multiple countries have consistently reported a significant increasing trend in the incidence of NTM infections. In Japan, the incidence of pulmonary disease caused by NTM infections increased from 15.8 to 19.2 cases per 100 000 population between 2013 and 2017, representing an increase of 17.7%. In Denmark, a national registry study covering 1991 to 2022 shows that the incidence of NTM-related pulmonary diseases has continuously increased over the 30-year period, with an average annual growth rate of 2.3%. The clinical manifestations of non-tuberculous mycobacterial pulmonary disease are non-specific and highly similar to those of pulmonary tuberculosis, but the treatment strategies are markedly different. Moreover, treatment schemes vary greatly among different NTM species. Therefore, rapid and accurate laboratory identification and species differentiation are essential. Conventional diagnostic methods such as smear microscopy and culture have technical limitations including low sensitivity and long turnaround time, making it difficult to meet the requirements of early and precise clinical diagnosis and treatment. Molecular diagnostic techniques, represented by real-time fluorescent PCR, have greatly shorte-ned detection duration and enabled rapid screening and differentiation of NTM. Genomic technologies, represented by next-generation sequencing and nanopore sequencing, can achieve integrated and precise identification of bacterial species to the subspecies level and detect drug resistance genes directly from clinical specimens, thereby guiding early clinical medication. Artificial intelligence technology demonstrates strong potential in integrating imaging features, clinical data, and even genomic information, and can assist in auxiliary diagnosis, optimize treatment schemes, and predict prognosis. The development of these novel NTM laboratory diagnostic techniques is driving the transformation of NTM diagnosis and treatment from an empirical model to an efficient, precise, and individualized model.

Key words： Non-tuberculous mycobacteria; Molecular diagnostic techniques; Genome sequencing; Biomarkers; Artificial intelligence

Cite this article

HUANG Hui , ZHANG Tingting , SUN Hongli . Current status and research advances in laboratory diagnosis of non-tuberculous mycobacteria[J]. Journal of Diagnostics Concepts & Practice, 2026 , 25(03) : 249 -259 . DOI: 10.16150/j.1671-2870.2026.03.001

References

[1] SAMINATHAN G, KUMAR V, SHANMUGAM S, et al. Revolutionizing non-tuberculous mycobacteria research: Advances in molecular diagnostics, phylogenetics, and clinical management[J]. J Microbiol Meth, 2025,237:107226.
[2] MALEKI M R, MOADDAB S R. The growing impact of nontuberculous mycobacteria: A multidisciplinary review of ecology, pathogenesis, diagnosis, and treatment[J]. Infect Med, 2025, 4(3):100203.
[3] CRISTANCHO-ROJAS C, VARLEY C D, LARA S C, et al. Epidemiology of Mycobacterium abscessus[J]. Clin Microbiol Infect, 2024, 30(6):712-717.
[4] FU H, ZHOU G, YANG Y, et al. Skin and soft tissue nontuberculous mycobacteria infection: A retrospective case series of 49 patients[J]. Aesthetic Plast Surg, 2025, 49(5):1543-1553.
[5] HARADA K, VU Q T, NISHIMURA Y, et al. Trends in nontuberculous mycobacterial disease mortality based on 2000-2022 data from 83 countries[J]. Int J Infect Dis, 2025,158:107932.
[6] ZHANG H, TANG M, LI D, et al. Applications and advances in molecular diagnostics: Revolutionizing non-tuberculous mycobacteria species and subspecies identification[J]. Front Public Health, 2024,12:1410672.
[7] YING C, ZHANG L, JIN X, et al. Advances in diagnosis and treatment of non-tuberculous mycobacterial lung di-sease[J]. Diagn Microbiol Infect Dis, 2024, 109(2):116254.
[8] SICILIANO M, AMISANO F, BAGNARINO J, et al. Epidemiology and drug susceptibility of nontuberculous mycobacteria in the province of Pavia (northern Italy): An overview[J]. Microorganisms, 2025, 13(11):2547.
[9] MAASDORP E, GHEBREKRISTOS Y, KHUMALO A, et al. Non-tuberculosis mycobacteria identified by line probe assays in respiratory and non-respiratory samples in South Africa between 2015 and 2019[J]. Tuberculosis, 2025,151:102610.
[10] EPPERSON L E, DAVIDSON R M, KAMMLADE S M, et al. Evaluation of the GenoType NTM-DR line probe assay for nontuberculous mycobacteria using whole genome sequences as reference standard[J]. Diagn Microbiol Infect Dis, 2024, 110(4):116526.
[11] DAHL V N, PEDERSEN A A, NORMAN A, et al. Clinical significance, species distribution, and temporal trends of nontuberculous mycobacteria, Denmark, 1991-2022[J]. Emerg Infect Dis, 2024, 30(9):1755-1762.
[12] HAMAGUCHI Y, MORIMOTO K, MITARAI S. Laboratory-based surveillance of nontuberculous mycobacterial pulmonary disease in Japan[J]. ERJ Open Res, 2025, 11(1):337-2024.
[13] GHAZI CHAKI S S, PIRSOLTAN S B, BEIG M, et al. Global trends in the proportion of macrolide-resistant Mycobacterium Species: A systematic review and meta-analysis[J]. PLoS One, 2025, 20(11):e0333521.
[14] 刘文彬, 唐磊明, 王敏, 等. Xpert MTB/RIF在涂阳患者中对NTM肺病的诊断价值及NTM菌种分布特征分析[J]. 中华全科医学, 2026, 24(2):275-279.
  LIU W B, TANG L M, WANG M, et al. The diagnostic value of Xpert MTB / RIF for NTM pulmonary disease in smear-positive patients and analysis of the species distribution characteristics of NTM[J]. Chin J Gen Pract, 2026, 24(2):275-279.
[15] 中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版)[J]. 中华结核和呼吸杂志, 2020, 43(11):918-946.
  Tuberculosis branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of nontuberculous mycobacterial disease (2020 Edition)[J]. Chin J Tuberc Respir Dis, 2020, 43(11):918-946.
[16] 中国研究型医院学会感染与炎症放射专业委员会, 中华医学会放射学分会传染病学组, 中国医师协会放射医师分会感染影像专业委员会, 等. 非结核分枝杆菌肺病影像诊断专家共识[J]. 中国研究型医院, 2021, 8(3):1-6.
  Radiology Committee on Infectious and Inflammatory Di-sease, Chinese Research Hospital Association; Infectious Diseases Sub-branch, Radiology Branch, Chinese Medical Association; Committee on Radiology of Infection, Radiologist Branch, Chinese Medical Doctor Association; et al. Imaging diagnostic criteria of non-tuberculous Mycobacterial lung disease[J]. J Chin Res Hosp, 2021, 8(3):1-6.
[17] XU T, ZHENG Y, XUE R, et al. Retrospective analysis of non-tuberculous mycobacterial skin infections: Diagnostic accuracy, treatment efficacy, and PCR-based species detection in a Chinese primary care hospital[J]. J Clin Microbiol, 2025, 63(12):e01065-e01025.
[18] RASHIDIFAR S, HARZANDI N, GHARAVI M J, et al. Direct detection and rapid speciation and subspeciation of Mycobacterium avium complex using five-target multiplex PCR and clinical correlations in HIV-positive patients in Tehran, Iran[J]. Diagn Microbiol Infect Dis, 2025, 113(4):117064.
[19] ATIYA N, ONG L T, LOH T C, et al. Diagnostic utility of auramine O smear microscopy for detecting non-tuberculous mycobacteria versus Mycobacterium tuberculosis complex in adult clinical samples: A 5-year retrospective study (2018-2022)[J]. BMC Infect Dis, 2025, 25(1):916.
[20] ABBEW E T, LORENT N, MESIC A, et al. Challenges and knowledge gaps in the management of non-tuberculous mycobacterial pulmonary disease in sub-Saharan African countries with a high tuberculosis burden: A scoping review[J]. BMJ Open, 2024, 14(1):e078818.
[21] World Health Organization. Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis[M]. Geneva: World Health Organization, 2011.
[22] SHAH S, ZAIDI K, ONYIA W. Mycobacterium porcinum disseminated infection in non-severely immunocompromised host[J]. Cureus, 2024: e55889.
[23] WEI S, MENG D, QIN J, et al. Disseminated Mycobacterium kansasii disease complicating Talaromyces marneffei infection in patient with anti-IFN-γ autoantibodies: A case report[J]. BMC Infect Dis, 2025, 25(1):1157.
[24] BUI T I, DOLAN J R, MUENKS C E, et al. Recovery of nontuberculous mycobacteria from non-cystic fibrosis respiratory specimens using a decontamination-free selective agar[J]. Eur J Clin Microbiol Infect Dis, 2025.
[25] BROWN-ELLIOTT B A, NASH K A, WALLACE R J JR. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria[J]. Clin Microbiol Rev, 2012, 25(3):545-582.
[26] KHARE R, BROWN-ELLIOTT B A. Culture, identification, and antimicrobial susceptibility testing of pulmonary nontuberculous mycobacteria[J]. Clin Chest Med, 2023, 44(4):743-755.
[27] KIM K J, OH S H, JEON D, et al. Isolation and antimicrobial susceptibility of nontuberculous mycobacteria in a tertiary hospital in Korea, 2016 to 2020[J]. Tuberc Respir Dis, 2023, 86(1):47-56.
[28] REN W, MAO Y, LI S, et al. Rapid Mycobacterium abscessus antimicrobial susceptibility testing based on antibiotic treatment response mapping via Raman Microspectroscopy[J]. Ann Clin Microbiol Antimicrob, 2023, 22(1):94.
[29] DALEY C L, IACCARINO J M, LANGE C, et al. Treatment of nontuberculous mycobacterial pulmonary disea-se: An official ATS/ERS/ESCMID/IDSA clinical practice guideline[J]. Eur Respir J, 2020, 56(1):2000535.
[30] XIE L, CAO J, YANG Y, et al. Simultaneous detection and differentiation ofMycobacterium tuberculosisand nontuberculous mycobacteria in smear-negative sputum by a multiplex PCR assay: A clinical feasibility study[J]. Microbiol Spectr, 2025, 13(7):e02316-e02324.
[31] LIU X, NIU H, GUO D, et al. Application value of nucleic acid MALDI-TOF MS in mycobacterial species identification and drug resistance detection in Mycobacterium tuberculosis[J]. Microbiol Spectr, 2025, 13(5):e01545-e01524.
[32] KIM K J, CHANG Y, YUN S G, et al. Evaluation of a commercial multiplex real-time PCR with melting curve analysis for the detection of Mycobacterium tuberculosis complex and five nontuberculous mycobacterial species[J]. Microorganisms, 2025, 13(1):26.
[33] ZHENG M, CHEN X, CHEN Q, et al. Employing multicolor melting curve analysis to rapidly identify non-tuberculous mycobacteria in patients with bronchiectasis: A study from a pulmonary hospital in the Fuzhou district of China, 2018-2022[J]. Crit Rev Immunol, 2024, 44(4):41-49.
[34] BRODA A, NIKOLAYEVSKYY V, CASALI N, et al. Experimental platform utilising melting curve technology for detection of mutations in Mycobacterium tuberculosis isolates[J]. Eur J Clin Microbiol Infect Dis, 2018, 37(7):1273-1279.
[35] HE W W, WANG W J, HUANG Z X, et al. Mycobacterium paragordonae pulmonary disease with rapidly gro-wing solitary lesions: A case report and literature review[J]. J Infect Dev Ctries, 2024, 18(10):1625-1631.
[36] SPENCER-WILLIAMS I, MEYER M, DEPAS W, et al. Assessing the impacts of lead corrosion control on the microbial ecology and abundance of drinking-water-associated pathogens in a full-scale drinking water distribution system[J]. Environ Sci Technol, 2023, 57(48):20360-20369.
[37] TERHALLE E, RADEMACHER J. Nichttuberkul?se mykobakterien: Diagnostische herausforderungen und individualisierte therapieans?tze[J]. Dtsch Med Wochenschr, 2025, 150(22):1360-1366.
[38] OPPERMAN C, STEYN J, MATTHEWS M C, et al. Targeted deep sequencing of mycobacteria species from extrapulmonary sites not identified by routine line probe assays: A retrospective laboratory analysis of stored clinical cultures[J]. IJID Reg, 2024,13:100464.
[39] FANG T, PENG L, LI Z, et al. Clinical evaluation of multiplex PCR for the differential diagnosis of major pathogenic mycobacteria in East China[J]. Medicine, 2025, 104(46):e45906.
[40] IVERSEN X E S, RASMUSSEN E M, FOLKVARDSEN D B, et al. Four novel nontuberculous mycobacteria species: Mycobacterium wendilense sp. nov., Mycobacterium burgundiense sp. nov., Mycobacterium kokjensenii sp. nov. and Mycobacterium holstebronense sp. nov. revived from a historical Danish strain collection[J]. Int J Syst Evol Microbiol, 2025, 75(1): 006620.
[41] LIU J, QIAN H, JIN J, et al. Use of metagenomic next-generation sequencing for accurate diagnosis of tuberculous pleurisy: A retrospective cohort study[J]. J Thorac Dis, 2025, 17(9):6771-6778.
[42] WANG L, CHEN Y, WANG Q, et al. Comparison of molecular testing methods for diagnosing non-tuberculous mycobacterial infections[J]. Eur J Clin Microbiol Infect Dis, 2025, 44(1):109-116.
[43] LIU J, WU M, ZHANG J, et al. First report of solitary cavitation nodules in the lungs with Mycobacterium canariasense[J]. J Infect Dev Ctries, 2024, 18(5):826-828.
[44] 宏基因组学测序技术在中重症感染中的临床应用共识专家组, 中国研究型医院学会脓毒症与休克专业委员会, 中国微生物学会微生物毒素专业委员会, 等. 宏基因组学测序技术在中重症感染中的临床应用专家共识(第一版)[J]. 中华危重病急救医学, 2020, 32(5):531-536.
  Consensus Group of Experts on Application of Metagenomic Next Generation Sequencing in the Pathogen Diagnosis in Clinical Moderate and Severe Infections; Professional Committee of Sepsis and Shock, Chinese Research Hospital Association; Professional Committee of Microbial Toxins, Chinese Society for Microbiology; et al. Expert consensus for the application of metagenomic next generation sequencing in the pathogen diagnosis in clinical moderate and severe infections (first edition)[J]. Chin Crit Care Med, 2020, 32(5):531-536.
[45] WEI W, CAO J, WU X C, et al. Diagnostic performance of metagenomic next-generation sequencing in non-tuberculous Mycobacterial pulmonary disease when applied to clinical practice[J]. Infection, 2023, 51(2):397-405.
[46] ZHANG X, TANG R, LI X, et al. tNGS reveals predominant mixed viral infections in a multicenter retrospective study[J]. Infect Drug Resist, 2025,18:5407-5418.
[47] LIN W H. Diagnostic value of nanopore sequencing technology in nontuberculous mycobacterial pulmonary disease[J]. Am J Transl Res, 2024, 16(8):4208-4215.
[48] CHENG L P, WANG L, WANG Y F, et al. Nanopore-targeted sequencing: A new and effective technique for the diagnosis of non-tuberculous mycobacteria pulmonary disease[J]. Int J Med Microbiol, 2025,320:151663.
[49] HUANG H L, LIN C H, LEE M R, et al. Sputum bacterial microbiota signature as a surrogate for predicting disease progression of nontuberculous mycobacterial lung disease[J]. Int J Infect Dis, 2024,149:107085.
[50] NAITO M, TAKEDA Y, EDAHIRO R, et al. NHERF2 as a novel biomarker for distinguishing MAC pulmonary di-sease from tuberculosis based on proteome analysis of serum extracellular vesicles[J]. Int J Mol Sci, 2025, 26(3):1155.
[51] CALHOUN K M, ARMANTROUT E, POCH K, et al. Prospective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis[J]. PLoS One, 2025, 20(3):e0309191.
[52] GARCIA B, WILMSKOETTER J, GRADY A, et al. Chest computed tomography features of nontuberculous mycobacterial pulmonary disease versus asymptomatic colonization: A cross-sectional cohort study[J]. J Thorac Imag, 2022, 37(3):140-145.
[53] MANI-VARNOSFADERANI A, GAO A, POCH K R, et al. Breath biomarkers associated with nontuberculosis mycobacteria disease status in persons with cystic fibrosis: A pilot study[J]. J Breath Res, 2022, 16(3):031001.
[54] LIU C J, LIU Y C, CHEN Y H, et al. AI-assisted differentiation of nontuberculous mycobacterial pulmonary disea-se from colonization: A multi-center study[J]. Insights Imag, 2025, 16(1):249.
[55] LIU C J, TSAI C C, KUO L C, ET AL. A deep learning model using chest X-ray for identifying TB and NTM-LD patients: A cross-sectional study[J]. Insights Imag, 2023, 14(1):67.
[56] MUKHERJEE D, WANG P, HOOI L, et al. Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteria[J]. Theranostics, 2022, 12(16):6848-6864.
[57] LEE S, LEE H W, KIM H J, et al. Deep learning-based prediction model using radiography in nontuberculous mycobacterial pulmonary disease[J]. Chest, 2022, 162(5):995-1005.
Options
Outlines

/

〈 〉